Published in J Clin Virol on November 01, 2009
Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol (2011) 1.47
A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol (2014) 1.11
Prevalence of human papillomavirus infection in women in Benin, West Africa. Virol J (2011) 1.08
Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int (2013) 0.97
HPV prevalence and type distribution in women with or without cervical lesions in the Northeast region of Romania. Virol J (2011) 0.89
Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol (2014) 0.87
Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis (2012) 0.87
Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. J Clin Microbiol (2013) 0.87
The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol (2013) 0.85
Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open (2016) 0.84
Protecting the underscreened women in developed countries: the value of HPV test. BMC Cancer (2014) 0.84
Interlaboratory reproducibility and proficiency testing within the human papillomavirus cervical cancer screening program in Catalonia, Spain. J Clin Microbiol (2014) 0.84
Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off. PLoS One (2014) 0.82
Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain. BMC Infect Dis (2012) 0.80
Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci (2012) 0.80
Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J Clin Microbiol (2012) 0.77
Human Papillomavirus Laboratory Testing: the Changing Paradigm. Clin Microbiol Rev (2016) 0.76
HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows. BMC Cancer (2016) 0.75
Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene (2006) 2.56
Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer (2004) 2.33
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
The effects of perceived stress, traits, mood states, and stressful daily events on salivary cortisol. Psychosom Med (1997) 2.12
Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol (2006) 2.02
Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer (2006) 1.83
Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer (2002) 1.83
Papillomavirus infection in rural women in southern India. Br J Cancer (2005) 1.79
Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol (2013) 1.77
Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer (2006) 1.62
HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer (2012) 1.53
HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer (2009) 1.50
Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur J Cancer (2003) 1.48
Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol (2011) 1.47
Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer (2006) 1.43
Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. Br J Cancer (2012) 1.34
Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer (2007) 1.32
[Flat penile lesions in the sexual transmission of human papillomavirus]. Ned Tijdschr Geneeskd (2008) 1.32
A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol (2005) 1.31
Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol (2014) 1.30
Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol (2008) 1.28
Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol (2006) 1.24
High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer (2007) 1.24
Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol (2005) 1.20
Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer (2008) 1.17
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer (2011) 1.16
Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer (2008) 1.16
Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer (2005) 1.13
Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer (2005) 1.12
Human papillomavirus infection in women with and without cervical cancer in Karachi, Pakistan. Br J Cancer (2010) 1.10
HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv (2004) 1.10
Clinical relevance of human papillomavirus testing in cytopathology. Cytopathology (2005) 1.08
Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene (2012) 1.06
A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol (2009) 1.05
KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br J Cancer (2013) 1.03
Individual differences in cortisol responses to a laboratory speech task and their relationship to responses to stressful daily events. Biol Psychol (1996) 1.03
TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients. Oral Dis (2013) 1.02
MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer (2008) 1.00
A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Cell Oncol (2009) 0.97
High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology. J Clin Virol (2009) 0.97
Specific p53 immunostaining patterns are associated with smoking habits in patients with oral squamous cell carcinomas. J Clin Pathol (2002) 0.97
Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol (2012) 0.96
Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol (2008) 0.96
HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer (2005) 0.94
Suprabasal p53 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland. J Clin Pathol (2002) 0.93
Promoter methylation analysis of WNT/β-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix. Gynecol Oncol (2011) 0.93
Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening. J Clin Microbiol (2009) 0.92
Effects of HPV detection in population-based screening programmes for cervical cancer; a Dutch moment. Gynecol Oncol (2005) 0.89
Role of paan chewing and dietary habits in cervical carcinoma in Chennai, India. Br J Cancer (2003) 0.89
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Arch (2012) 0.88
The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency. Br J Cancer (2007) 0.88
Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer (2010) 0.88
Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol (2014) 0.87
Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. J Clin Microbiol (2013) 0.87
The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol (2013) 0.85
Childhood brain tumours due to germline bi-allelic mismatch repair gene mutations. Clin Genet (2011) 0.85
High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products. J Clin Virol (2009) 0.83
Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing. Br J Cancer (2012) 0.81
Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer (2014) 0.81
High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol (2012) 0.80
Optimal strategies to identify aberrant intra-epithelial lymphocytes in refractory coeliac disease. J Clin Immunol (2014) 0.79
Vaccination against HPV: indications for women and the impact on the cervical screening programme. BJOG (2008) 0.78
Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate. J Clin Pathol (2006) 0.78
Human papillomavirus and cervical cancer from a prospective study in Khon Kaen, Northeast Thailand. Int J Gynecol Cancer (2006) 0.78
High-risk human papillomavirus is present in cytologically false-negative smears: an analysis of "normal" smears preceding CIN2/3. J Clin Pathol (2007) 0.78
Dimerization of glycoprotein E(rns) of classical swine fever virus is not essential for viral replication and infection. Arch Virol (2005) 0.77
Detection of human papillomavirus DNA in primary squamous cell carcinoma and metastases. Br J Dermatol (2006) 0.77
Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation. Histopathology (2007) 0.76
HrHPV-testing in a university hospital gynecology outpatient clinic: recommendations for clinical practice. Gynecol Oncol (2011) 0.75
Corrections. Lancet Infect Dis (2015) 0.75